The next-generation PI3Kα inhibitor STX-478 is associated with reduced metabolic toxicities and a favorable safety profile in PIK3CA-mutant breast and gynecologic cancers, distinguishing it from other agents. @UHhospitals @cwrusom #bcsm #gyncsm #oncology
#bcsm #gyncsm #oncology